Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptevo Therapeutics Inc
(NQ:
APVO
)
0.2668
-0.0232 (-8.00%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptevo Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
November 20, 2024
Via
ACCESSWIRE
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
November 11, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
November 07, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 29, 2024
Via
Benzinga
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
October 29, 2024
Via
ACCESSWIRE
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
August 13, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
May 14, 2024
Via
ACCESSWIRE
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
October 23, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 23, 2024
Via
Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 21, 2024
Via
Benzinga
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
October 21, 2024
Via
Benzinga
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 18, 2024
Via
ACCESSWIRE
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
September 17, 2024
Via
Benzinga
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 16, 2024
Via
ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
September 16, 2024
Via
ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
September 13, 2024
Via
ACCESSWIRE
APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q2 2024
August 08, 2024
APVO stock results show that Aptevo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
August 08, 2024
Via
ACCESSWIRE
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 18, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
July 18, 2024
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!
Via
InvestorPlace
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
July 18, 2024
Via
Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 17, 2024
Via
Benzinga
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
July 17, 2024
Via
Benzinga
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
July 01, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
June 28, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 17, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 17, 2024
We have all of the biggest pre-market stock movers that investors are going to want to keep an eye on for Monday morning!
Via
InvestorPlace
Aptevo Participating in the BIO International Convention
June 03, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.